Top Story

FDA approves meropenem for infants with abdominal infections

May 29, 2015

The FDA today approved the antibiotic meropenem for the treatment of abdominal infections in neonates and infants aged younger than 3 months, according to a press release from the NIH.

Previously approved to treat complicated intra-abdominal infections and complicated skin infections in adults and older children, meropenem has been prescribed “off-label” for preterm infants with serious abdominal infections due to a lack of an effective alternative.

Meeting News Coverage

Synovial tissue may be immunomodulated by PMMA-spacers in two-stage revision TJA

May 29, 2015
PRAGUE — According to data presented at the 16th EFORT Congress, synovial tissue in patients undergoing two-stage revision total joint arthroplasty may be…
In the Journals

Cognitive skills decrease with history of severe infections

May 29, 2015
A history of severe infections may be associated with impaired general cognitive ability, according to recently published data. “Infections have previously been…
In the Journals

Cognitive skills decrease with history of severe infections

May 29, 2015
A history of severe infections may be associated with impaired general cognitive ability, according to recently published data.“Infections have previously been…
Drug Pipeline

Merck submits new drug application for grazoprevir/elbasvir for HCV

May 29, 2015
Merck announced that the company has submitted a new drug application to the FDA for grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C genotype…
More News Headlines »
CME
Management of Pediatric Conjunctivitis and Otitis/Conjunctivitis Syndrome

Management of Pediatric Conjunctivitis and Otitis/Conjunctivitis Syndrome

This activity is supported by an educational grant from Alcon Research, LTD.

More »
Meeting News Coverage Video
VIDEO: C-SURFER: Patients with kidney disease, HCV achieve high rates of SVR

VIDEO: C-SURFER: Patients with kidney disease, HCV achieve high rates of SVR

April 25, 2015
VIENNA — Howard Monsour Jr., MD, chief of hepatology, Houston Methodist Hospital, Texas, discussed results of…
More »
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
morganatic-roan